HSV1 Oncolysis-Immune Checkpoint Inhibition Therapy for Breast Cancer Meningeal Metastases
[Technical Report, Annual Report]
MASSACHUSETTS GENERAL HOSPITAL BOSTON
Pagination or Media Count:
Meningeal metastasis is a terminal disease classified under stage IV breast cancer which affects 10-15 of patients. Currently there is no cure limiting survival to less than 4months. The research conducted during this period explored a novel treatment approach which had hitherto not been investigated for breast cancer meningeal metastases that of combination therapy with oncolytic HSV1 and immune checkpoint inhibition. Based on our initial investigation, the combination treatment approach was therapeutic for breast cancer meningeal metastases in our murine model. The tumor growth was inhibited following combination therapy survival was prolonged together with a remarkable recovery of neurological symptoms. Cancer-immune pathways regulated during combination therapy for this disease were identified for further investigation.
- Medicine and Medical Research